Clinical trials: Ischemic Reperfusion Injury
End Stage Renal Disease, Chronic Kidney Diseases
Berinert (C1INH) vs Placebo for DGF/IRI
This is a Phase I/II double-blind, randomized, placebo-controlled study assessing safety and limited efficacy of intraoperative C1INH (500U/kidney) vs.
- Trial name
- NCT04696146
- Testing
- Berinert
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cedars-Sinai Medical Center
Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery, Inflammatory Reaction After Neonatal Cardiac Surgery
Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass
Around 7500 neonates born yearly in the United States have complex congenital heart disease that require surgical repair in the first few days of life.
- Trial name
- NCT02151877
- Testing
- Inhaled Nitric Oxide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Diabetes
Nitrite Infusion in Islet Cell Transplantation
This study seeks to investigate the effects of administering nitrite to pancreatic islet cells that have been removed from a patient for autotransplantation.
- Trial name
- NCT03544242
- Testing
- Control, Pre-Isolation Infusion, Post-Isolation Infusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Alabama at Birmingham
Cardiac Arrest
Remote Ischemic Conditioning to Enhance Resuscitation (RICE) Pilot
Following resuscitation from out-of-hospital cardiac arrest (OHCA), reperfusion injury can cause cell damage in the heart and brain.
- Trial name
- NCT04265807
- Testing
- Active Remote Ischemic Conditioning
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Reperfusion Injury
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)
The purpose of this study is to establish the effectiveness of the combined drug approach (anti-thrombin III, infliximab, apotransferrin, human recombinant erythropoietin beta, C1-inhibitor, glutathione, alfa-tocopherol…
- Trial name
- CAPITL (NCT02251041)
- Testing
- Antithrombin-III, Infliximab, Apotransferrin
- Where
- Belgium
- Volunteers
- 143 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Ischemia-Reperfusion Injury, Kidney Diseases
Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8.
- Trial name
- NCT00248040
- Testing
- Reparixin continuous infusion, reparixin intermittent infusion
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Dompé Farmaceutici S.p.A
Ischemia-reperfusion Injury in Liver Transplant, Early Allograft Dysfunction
Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation
The objective of the study is to evaluate the efficacy and safety of Reparixin treatment (2.772 mg/kg body weight/hour intravenous continuous infusion for 7 days) based on incidence of early allograft dysfunction within the first…
- Trial name
- NCT03031470
- Testing
- Reparixin, Control
- Where
- 7 sites in Belarus, Russia
- Volunteers
- 40 people
- Sponsor
- Dompé Farmaceutici S.p.A
Ischemia Reperfusion Injury
Purge Vs no Purge in Living Donor Liver Transplantation Recipients
The investigators tested the impact of purging the graft contents and mesenteric blood into the systemic circulation versus washing out this volume out of the circulation in living donor liver transplantation recipients.
- Trial name
- PNP (NCT02540447)
- Testing
- Purge
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Mansoura University
Cardiac Arrest
Reoxygenation After Cardiac Arrest II (REOX II Study)
The broad objective of this study is to test the association between hyperoxia exposure after resuscitation from cardiac arrest and outcome.
- Trial name
- REOX II (NCT02698826)
- Testing
- Protocol for rapid FiO2 optimization
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cooper Norcross Health
End Stage Renal Disease, Kidney Failure
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
The use of C1INH (Berinert) in patients receiving deceased donor kidney transplants with high risk for delayed graft function (DGF) may show significant improvement in outcomes post transplant compared with patients that do not…
- Conditions
- End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
- Trial name
- C1INHDGF (NCT02134314)
- Testing
- C1 Esterase Inhibitor
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Cedars-Sinai Medical Center
Myocardial Ischemia
The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart
Ischemia reperfusion injury may be attenuated by HO-1 induction. Our previous data confirmed strong HO-1 induction in peripheral blood cells following heme arginate infusion in healthy humans.
- Trial name
- NCT02314780
- Testing
- Heme arginate 3mg/kg, Heme arginate 1mg/kg
- Where
- Austria
- Volunteers
- 31 people
- Sponsor
- Martin Andreas, M.D.
Liver Transplantation, Ischemia/Reperfusion Injury
Effect of Nitric Oxide (NO) on Ischemic/Reperfusion Injury During Extended Donor Criteria (EDC) Liver Transplantation
In this study, the researchers propose to investigate the efficacy of inhaled nitric oxide to prevent ischemia-reperfusion (I/R) hepatocyte injury in patients who receive extended donor criteria(EDC)liver grafts based on changes…
- Conditions
- Liver Transplantation, Ischemia/Reperfusion Injury, Oxidative Injury
- Trial name
- NCT00948194
- Testing
- Nitric Oxide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Ischemia-Reperfusion Injury, Lung Transplantation
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
The objective of this clinical study was to evaluate whether CXCL8 (CXC ligand 8 [formerly interleukin (IL)-8]) inhibition with repertaxin leads to reduced severity of primary graft dysfunction, as the result of improved…
- Trial name
- NCT00224406
- Testing
- Repertaxin
- Where
- 6 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- Dompé Farmaceutici S.p.A
Ischemic Heart Disease, Bone Marrow Cells
Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease
The purpose of this study evaluate the effect of the method of administration of autologous bone marrow mononuclear cells for the duration of of functioning aorto-coronary bypass grafts in the surgical treatment of coronary heart…
- Conditions
- Ischemic Heart Disease, Bone Marrow Cells, Coronary Artery Bypass Grafting (CABG), Heart Failure, Diastolic
- Trial name
- TAMIS (NCT02059512)
- Testing
- Group 1, Group 0, Group 2
- Where
- Russia
- Volunteers
- 117 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Myocardial Infarction, Reperfusion Injury
Pilot Study of Edaravone to Treat Acute Myocardial Infarction
Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries.
- Trial name
- NCT00265239
- Testing
- edaravone
- Where
- Japan
- Volunteers
- 104 people
- Sponsor
- Kumamoto University
Ischemic Reperfusion Injury, Other Reconstructive Surgery
RIPC During Free Flap With Preoperative Radiotherapy
Remote ischemic preconditioning (RIPC) has shown organ-protective effects in many clinical settings including patients with ischemic heart disease.
- Conditions
- Ischemic Reperfusion Injury, Other Reconstructive Surgery, Radiotherapy
- Trial name
- NCT03535623
- Testing
- remote ischemic preconditioning (RIPC)
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Seoul National University Hospital
Reperfusion Injury, Liver Injury
Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation
This blinded, placebo-controlled study will administer inhaled nitric oxide to patients undergoing liver transplantation. The purpose of the study is to test if inhaled nitric oxide prevents liver injury associated with the…
- Trial name
- NCT00582010
- Testing
- inhaled nitric oxide, nitrogen gas
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Alabama at Birmingham
Early Allograft Dysfunction, Ischemic Reperfusion Injury
Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
The purpose of this study is to determine whether the Tacrolimus added to histidine-tryptophan-ketoglutarate (HTK) solution given through intraportal and intraarterial infusion during back-table procedure is capable of reducing…
- Conditions
- Early Allograft Dysfunction, Ischemic Reperfusion Injury, Liver Transplantation, Hyperfibrinolysis
- Trial name
- PATAC (NCT01887171)
- Testing
- Tacrolimus
- Where
- Belarus
- Volunteers
- 86 people
- Sponsor
- Republican Scientific and Practical Center for Organ and Tissue Transplantation
Reperfusion Injury, STEMI
Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of IV administered elamipretide (also…
- Trial name
- EMBRACE (NCT01572909)
- Testing
- Bendavia (MTP-131)
- Where
- 30 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Stealth BioTherapeutics Inc.
Renal Artery Obstruction, Hypertension, Renovascular
Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery
This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury…
- Conditions
- Renal Artery Obstruction, Hypertension, Renovascular, Ischemia Reperfusion Injury
- Trial name
- EVOLVE (NCT01755858)
- Testing
- Bendavia
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Stealth BioTherapeutics Inc.